Alivus Life Sciences [GLS] vs Marksans Pharma [MARKSANS] Detailed Stock Comparison
Alivus Life Sciences
NSE
Loading...
Marksans Pharma
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Alivus Life Sciences wins in 11 metrics, Marksans Pharma wins in 8 metrics, with 0 ties. Alivus Life Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alivus Life Sciences | Marksans Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 31.45 | 22.35 | Marksans Pharma |
| Price-to-Book Ratio | 5.23 | 3.17 | Marksans Pharma |
| Debt-to-Equity Ratio | 0.63 | 12.93 | Alivus Life Sciences |
| PEG Ratio | 22.31 | -0.65 | Marksans Pharma |
| EV/EBITDA | 21.33 | 15.87 | Marksans Pharma |
| Profit Margin (TTM) | 19.21% | 13.20% | Alivus Life Sciences |
| Operating Margin (TTM) | 23.53% | 12.42% | Alivus Life Sciences |
| EBITDA Margin (TTM) | 23.53% | 12.42% | Alivus Life Sciences |
| Return on Equity | 17.18% | 15.29% | Alivus Life Sciences |
| Return on Assets (TTM) | 11.43% | 11.75% | Marksans Pharma |
| Free Cash Flow (TTM) | $2.85B | $337.45M | Alivus Life Sciences |
| Dividend Yield | N/A | 0.62% | N/A |
| 1-Year Return | -10.54% | -29.25% | Alivus Life Sciences |
| Price-to-Sales Ratio (TTM) | 6.03 | 2.95 | Marksans Pharma |
| Enterprise Value | $128.55B | $74.90B | Alivus Life Sciences |
| EV/Revenue Ratio | 5.83 | 2.82 | Marksans Pharma |
| Gross Profit Margin (TTM) | 55.55% | 57.77% | Marksans Pharma |
| Revenue per Share (TTM) | $180 | $59 | Alivus Life Sciences |
| Earnings per Share (Diluted) | $34.48 | $7.73 | Alivus Life Sciences |
| Beta (Stock Volatility) | 0.16 | 1.26 | Alivus Life Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Alivus Life Sciences vs Marksans Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alivus Life Sciences | 0.58% | -2.95% | -7.86% | -12.05% | 6.42% | -7.52% |
| Marksans Pharma | -0.51% | -6.43% | -25.08% | -32.29% | -17.21% | -44.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alivus Life Sciences | -10.54% | 114.19% | 25.81% | 25.81% | 25.81% | 25.81% |
| Marksans Pharma | -29.25% | 221.57% | 262.50% | 98.21% | 4,245.38% | 487.01% |
Performance & Financial Health Analysis: Alivus Life Sciences vs Marksans Pharma
| Metric | GLS | MARKSANS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹133.05B | ₹78.31B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 62,523 | 2,626,906 |
| 90 Day Avg. Volume | 105,168 | 1,884,706 |
| Last Close | ₹947.20 | ₹168.60 |
| 52 Week Range | ₹850.00 - ₹1,335.10 | ₹166.75 - ₹358.70 |
| % from 52W High | -29.05% | -53.00% |
| All-Time High | ₹1,335.10 (Sep 16, 2024) | ₹358.70 (Dec 02, 2024) |
| % from All-Time High | -29.05% | -53.00% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.15% | 0.05% |
| Quarterly Earnings Growth | -0.20% | -0.34% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.13% |
| Operating Margin (TTM) | 0.24% | 0.12% |
| Return on Equity (TTM) | 0.17% | 0.15% |
| Debt to Equity (MRQ) | 0.63 | 12.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹207.20 | ₹54.44 |
| Cash per Share (MRQ) | ₹36.43 | ₹15.58 |
| Operating Cash Flow (TTM) | ₹4.17B | ₹2.42B |
| Levered Free Cash Flow (TTM) | ₹2.01B | ₹3.81B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.62% |
| Last 12-Month Dividend | ₹0.00 | ₹1.40 |
Valuation & Enterprise Metrics Analysis: Alivus Life Sciences vs Marksans Pharma
| Metric | GLS | MARKSANS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 31.45 | 22.35 |
| Forward P/E | 22.31 | 14.39 |
| PEG Ratio | 22.31 | -0.65 |
| Price to Sales (TTM) | 6.03 | 2.95 |
| Price to Book (MRQ) | 5.23 | 3.17 |
| Market Capitalization | ||
| Market Capitalization | ₹133.05B | ₹78.31B |
| Enterprise Value | ₹128.55B | ₹74.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.83 | 2.82 |
| Enterprise to EBITDA | 21.33 | 15.87 |
| Risk & Other Metrics | ||
| Beta | 0.16 | 1.26 |
| Book Value per Share (MRQ) | ₹207.20 | ₹54.44 |
Financial Statements Comparison: Alivus Life Sciences vs Marksans Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GLS | MARKSANS |
|---|---|---|
| Revenue/Sales | ₹6.42B | ₹6.20B |
| Cost of Goods Sold | ₹2.85B | ₹2.62B |
| Gross Profit | ₹3.57B | ₹3.58B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.75B | ₹770.22M |
| EBITDA | ₹2.01B | ₹1.06B |
| Pre-Tax Income | ₹1.85B | ₹765.98M |
| Income Tax | ₹481.87M | ₹183.96M |
| Net Income (Profit) | ₹1.37B | ₹582.02M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GLS | MARKSANS |
|---|---|---|
| Cash & Equivalents | ₹4.46B | ₹4.96B |
| Total Current Assets | ₹20.96B | ₹22.04B |
| Total Current Liabilities | ₹4.64B | ₹4.77B |
| Long-Term Debt | ₹133.80M | ₹2.63B |
| Total Shareholders Equity | ₹25.38B | ₹24.89B |
| Retained Earnings | N/A | ₹14.22B |
| Property, Plant & Equipment | ₹8.04B | ₹185.74M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GLS | MARKSANS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GLS | MARKSANS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 62,523 | 2,626,906 |
| Average Daily Volume (90 Day) | 105,168 | 1,884,706 |
| Shares Outstanding | 122.53M | 453.16M |
| Float Shares | 30.63M | 214.46M |
| % Held by Insiders | 0.76% | 0.46% |
| % Held by Institutions | 0.07% | 0.17% |
Dividend Analysis & Yield Comparison: Alivus Life Sciences vs Marksans Pharma
| Metric | GLS | MARKSANS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.40 |
| Last 12-Month Dividend Yield | N/A | 0.62% |
| 3-Year Avg Annual Dividend | ₹18.00 | ₹0.72 |
| 3-Year Avg Dividend Yield | 3.82% | 0.40% |
| 3-Year Total Dividends | ₹54.00 | ₹2.15 |
| Ex-Dividend Date | Oct 17, 2023 | Aug 01, 2025 |